Raymond James initiated coverage of Bausch Health with a Market Perform rating and $8 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHC:
- Bausch Health call volume above normal and directionally bullish
- Bausch Health Defends XIFAXAN® Patent Again
- Bausch Health files patent infringement lawsuit against Norwich Pharmaceuticals
- Bausch Health announces added Canadian public drug plan listings for UCERIS
- Paulson buys Carrols, exits SSR Mining in Q1